Hormonal therapy: historical perspective to future directions (Q34187285)

31 July 2017

1 reference

title

Hormonal therapy: historical perspective to future directions (English)

1 reference

31 July 2017

David G Mcleod

1

1 reference

PubMed ID

12667881

31 July 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

31 July 2017

1 reference

31 July 2017

61

1 reference

31 July 2017

2 Suppl 1

1 reference

31 July 2017

3-7

1 reference

31 July 2017

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Epidemiology of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Design considerations for efficient prostate cancer chemoprevention trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

The evolving role of hormone therapy in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

The role of diethylstilbestrol in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Early versus late hormonal therapy: debating the issues.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Current concepts in androgen deprivation therapy--is there a "best" endocrine treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Molecular basis of androgen insensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902393-2

7 January 2021

10.1016/S0090-4295(02)02393-2

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

12667881